Business

Molecule to Medicine: How Daraxonrasib is Rewriting Pancreatic Cancer Drug Development

THE STREET·3h ago·3 min read

Photograph via The Street

RSS SUMMARY · AGGREGATED FROM THE STREET

Monash University's Andrew R. Snyder, PhD. joins the show to discuss Daraxonrasib, a novel RAS(ON) inhibitor, doubled median overall survival (~13.2 vs ~6.6–6.7 months) versus chemotherapy in a 500‑patient phase 3 trial for previously treated metastatic pancreatic cancer (RASolute 302; NEJM, May …

The full story continues on The Street.

Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.

Read on The Street →

The Source

The full story continues on The Street.

THE STREET

National mall footwear giant closes 82 stores as shoppers trade up

Apple announces store closures amid major retail problem

White House sends blunt message to Warsh as Fed rate fears rise

Education Dept enforces critical deadline for borrowers

On this beat

National mall footwear giant closes 82 stores as shoppers trade up

We All Hate Meetings—Here’s How to Make Them Work

Canada’s economy posts biggest trade surplus in more than a year

5 interesting things we just learned about the people who use Lovable